Skip navigation

Calls to Action

The Seaver Center for Autism Research and Treatment, Mount Sinai Medical Center, New York, NY

Clinical research projects currently seeking participants:
January 01, 2008

The Seaver Center for Autism Research and Treatment/Mount Sinai Medical Center, New York, NY

Child Study:

"Divalproex Sodium vs. Placebo in Child and Adolescent Autistic Disorder"

Divalproex Sodium (Depakote) Study examines efficacy of Divalproex sodium, a drug that is already FDA-approved for the treatment of epilepsy or manic episodes associated with bipolar disorder. This mood stabilizer may help in reducing autistic symptoms, such as impulsivity, aggression, and social and language deficits, in children/adolescents with autism. Eligibility is as follows:

  • Participant must be between 5 and 17 years of age.
  • Participant must have diagnosis of Autism, Asperger's or PDD-NOS
  • Participant must be able to taper off current psychotropic medications
  • Participant must exhibit signs of aggressive behavior.

For information about enrolling in this program, contact Denise Soto at (888) 777-6227, ext. 38, or via e-mail at dsoto@naar.org.


The Seaver Center for Autism Research and Treatment/Mount Sinai Medical Center, New York, NY

Child Study:

"Citalopram (Celexa Study)"

Citalopram (Celexa Study) - This study examines the efficacy of Citalopram, a selective serotonin reuptake inhibitor. Dysregulation of the serotonin system has been linked to autistic symptoms and to repetitive behaviors. This study aims to improve repetitive behaviors and symptoms in children and adolescents with autism spectrum disorders. Serotonin levels in the blood will also be measured in conjunction with this study. Eligibility is as follows:

  • Participant must be between 5 and 17 years of age.
  • Participant must have diagnosis of Autism, Asperger's or PDD-NOS
  • Participant must be able to taper off current psychotropic medications, high levels of repetitive behavior.

For information about enrolling in this program, contact Denise Soto at (888) 777-6227, ext. 38, or via e-mail at dsoto@naar.org


The Seaver Center for Autism Research and Treatment/Mount Sinai Medical Center, New York, NY

Child Study:

"Levetriacetam (Keppra) Study"

Levetiracetam (Keppra) Study examines the efficacy of a new FDA-approved anti-epileptic medication. Pilot studies indicate that this medication may be helpful in reducing autistic symptoms, primarily hyperactivity as well as other associated symptoms in children and adolescents with autism. Eligibility is as follows:

  • Participant must be between 5 and 17 years of age.
  • Participant must have diagnosis of Autism, Asperger's or PDD-NOS
  • Participant must be able to taper off current psychotropic medications, high levels of repetitive behavior.

For information about enrolling in this program, contact Denise Soto at (888) 777-6227, ext. 38, or via e-mail at dsoto@naar.org.


The Seaver Center for Autism Research and Treatment/Mount Sinai Medical Center, New York, NY

Genetics Repository:

Genetics Repository - In conjunction with these two other studies, a genetics component will be offered to those interested in donating blood to the genetics repository at the National Institute of Mental Health. These blood samples will be analyzed as part of a larger national database. Parents of autistic children will also be encouraged to donate samples so that scientists can look at chromosomal linkage between healthy parents and their autistic children. Eligibility is as follows:

  • Participant must be enrolled in the Citalopram (Celexa) Study
  • Or have more than one child/sibling with an Autism Spectrum Disorder.

For information about enrolling in this program, contact Denise Soto at (888) 777-6227, ext. 38, or via e-mail at dsoto@naar.org.


The Seaver Center for Autism Research and Treatment/Mount Sinai Medical Center, New York, NY

Adult Study:

"Fluoxetine vs. Placebo in Adult Autistic Disorder"

Fluoxetine (Prozac Study) examines the efficacy of Fluoxetine, a medication from the family of drugs known as selective reuptake inhibitors, or SSRI's. Fluoxetine is already FDA-approved for the treatment of patients suffering from depression and other mood disorders, and researchers believe it may be helpful in improving compulsivity, depression, anxiety, and social impairments in children, adolescents, and adults with autism spectrum disorders. Eligibility is as follows:

  • Participant must be an adult between the ages of 18-65
  • Participant must be diagnosed with an autism spectrum disorder, high levels of repetitive behavior
  • Participant must be able to taper off current psychotropic medications or are not taking other medications.

For information about enrolling in this program, contact Denise Soto at (888) 777-6227, ext. 38, or via e-mail at dsoto@naar.org
.


The Seaver Center for Autism Research and Treatment/Mount Sinai Medical Center, New York, NY

"5HT Imaging"

5HT Imaging - This study will be done in conjunction with Columbia University. Using Positron Emission Tomography (PET), this study will examine the activity of serotonin receptors in the brains of adults with autism spectrum disorders as compared to healthy controls. Eligibility is as follows:

  • Participant must be between 18 and 40 years of age.
  • Participant must be diagnosed with an Autism Spectrum Disorder.
  • Participant must be free of psychotropic medication.

For information about enrolling in this program, contact Denise Soto at (888) 777-6227, ext. 38, or via e-mail at dsoto@naar.org.


The Seaver Center for Autism Research and Treatment/Mount Sinai Medical Center, New York, NY

"Neuroimaging Studies"

Neuroimaging Studies analyze images of brain regions associated with emotional processing in subjects with autism spectrum disorders. Using positron emission tomography (PET) and magnetic resonance imaging (MRI), we aim to link abnormal brain metabolism with specific compulsive and social deficit symptoms, evaluate predictors of pharmacological treatment outcome and assess the role of serotonin function in the brains of autistic adults. Another study using an MRI and PET scan examines the amount of white matter (myelin) and its connections in the brain. Eligibility is as follows:

  • Participant must be between 18 and 40 years of age.
  • Participant must be diagnosed with an Autism Spectrum Disorder.
  • Participant must be free of psychotropic medication.

For information about enrolling in this program, contact Denise Soto at (888) 777-6227, ext. 38, or via e-mail at
dsoto@naar.org.


The Seaver Center for Autism Research and Treatment/Mount Sinai Medical Center, New York, NY

Multiplex Families only:

"Family Genetic Studies Program"

Family Genetic Studies Program are a number of studies being conducted exploring the genetic component of autism spectrum disorders, focusing on families with more than one child with autism spectrum disorders. These studies combine the direct study of families of autistic individuals with the latest advances in molecular biology and quantitative genetics. Eligibility is as follows:

  • Families with more than one child with an autism spectrum disorder.

For information about enrolling in this program, contact Denise Soto at (888) 777-6227, ext. 38, or via e-mail at dsoto@naar.org.

Back to Parents As Partners In Research Information